OncoMatch/Clinical Trials/NCT07137819
Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis
Is NCT07137819 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Topical treatment for actinic keratosis of face and scalp.
Treatment: Topical treatment — The goal of this clinical trial is to show superiority of Veregen® 10% ointment to Placebo measured by complete (100%) clearance of a pre-defined treatment area (TA) following a treatment period of 12 weeks and a 4-weeks post-treatment (PT) period (i.e., after 16 weeks at most in patients without complete clearance at the end of the treatment (EoT) period).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Grade: Olsen grade IOlsen grade II (Olsen)
AK lesions of the TA must be clinically typical AK lesions of Olsen grade I and/or grade Olsen grade II.
Prior therapy
Cannot have received: curettage
Curettage for/in a period of 12 weeks
Cannot have received: photodynamic therapy
Photodynamic therapy for/in a period of 12 weeks
Cannot have received: topical inhibitors of Src tyrosine kinase signaling and tubulin polymerization (tirbanibulin)
Topical inhibitors of Src tyrosine kinase signaling and tubulin polymerization (e.g.,Tirbanibulin) for/in a period of 12 weeks
Cannot have received: topical retinoids
Topical retinoids for/in a period of 6 weeks
Cannot have received: topical diclofenac preparations
Topical diclofenac preparations for/in a period of 6 weeks
Cannot have received: topical 5-fluorouracil preparations
Topical 5-fluorouracil preparations for/in a period of 6 weeks
Cannot have received: topical immunomodulators (imiquimod)
Topical immunomodulators (e.g., Imiquimod) for/in a period of 6 weeks
Cannot have received: topical steroids
Topical steroids for/in a period of 4 weeks
Cannot have received: cryo-, thermo- or chemodestruction
Cryo-, thermo- or chemodestruction for/in a period of 4 weeks
Cannot have received: surgical excision
Surgical excision for/in a period of 4 weeks
Cannot have received: systemic immunomodulators or immunosuppressive therapies
Initiation of treatment with the following systemic treatments for any indication within 2 weeks before Baseline: Immunomodulators or immunosuppressive therapies
Cannot have received: systemic diclofenac
Initiation of treatment with Diclofenac within 2 weeks before Baseline
Cannot have received: systemic corticosteroids
Initiation of treatment with Corticosteroids (oral or injectable) within 2 weeks before Baseline
Cannot have received: inhaled corticosteroids (beclomethasone, fluticasone)
Initiation of treatment with Inhaled corticosteroids (>1200 µg/day for beclomethasone, or >600 µg/day for fluticasone) within 2 weeks before Baseline
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07137819 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior curettage, photodynamic therapy, topical inhibitors of Src tyrosine kinase signaling and tubulin polymerization disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify